Use of adenovirus type-5 vectored vaccines: a cautionary tale.
作者信息
Buchbinder Susan P, McElrath M Juliana, Dieffenbach Carl, Corey Lawrence
机构信息
Bridge HIV, San Francisco Department of Public Health, San Francisco, CA 94102, USA; Department of Medicine and Department of Epidemiology, University of California, San Francisco, CA, USA.
Fred Hutchinson Cancer Research Institute, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, University of Washington, Seattle, WA, USA.
出版信息
Lancet. 2020 Oct 31;396(10260):e68-e69. doi: 10.1016/S0140-6736(20)32156-5. Epub 2020 Oct 19.
Abstract
摘要
相似文献
1
Use of adenovirus type-5 vectored vaccines: a cautionary tale.
Lancet. 2020 Oct 31;396(10260):e68-e69. doi: 10.1016/S0140-6736(20)32156-5. Epub 2020 Oct 19.
2
Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines.
Mol Ther. 2020 Nov 4;28(11):2303-2304. doi: 10.1016/j.ymthe.2020.10.002. Epub 2020 Oct 9.
3
Developing a SARS-CoV-2 Vaccine at Warp Speed.
JAMA. 2020 Aug 4;324(5):437-438. doi: 10.1001/jama.2020.12190.
4
The COVID-19 vaccine development landscape.
Nat Rev Drug Discov. 2020 May;19(5):305-306. doi: 10.1038/d41573-020-00073-5.
5
Developing Covid-19 Vaccines at Pandemic Speed.
N Engl J Med. 2020 May 21;382(21):1969-1973. doi: 10.1056/NEJMp2005630. Epub 2020 Mar 30.
6
The Russian vaccine for COVID-19.
Lancet Respir Med. 2020 Nov;8(11):e85-e86. doi: 10.1016/S2213-2600(20)30402-1. Epub 2020 Sep 5.
7
The race for coronavirus vaccines: a graphical guide.
Nature. 2020 Apr;580(7805):576-577. doi: 10.1038/d41586-020-01221-y.
8
[Not Available].
MMW Fortschr Med. 2020 Apr;162(7):56. doi: 10.1007/s15006-020-0398-7.
9
Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic.
CMAJ. 2020 Aug 24;192(34):E982-E985. doi: 10.1503/cmaj.201237. Epub 2020 Jul 9.
10
COVID-19 vaccines: time to talk about the uncertainties.
Nature. 2020 Oct;586(7830):475. doi: 10.1038/d41586-020-02944-8.
引用本文的文献
1
Progress and Recent Developments in HIV Vaccine Research.
Vaccines (Basel). 2025 Jun 26;13(7):690. doi: 10.3390/vaccines13070690.
2
Developing the next-generation of adenoviral vector vaccines.
Hum Vaccin Immunother. 2025 Dec;21(1):2514356. doi: 10.1080/21645515.2025.2514356. Epub 2025 Jul 1.
3
Immune response induced by the recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (Ad5-nCoV) in persons living with HIV (PLWH).
PLoS One. 2025 Jun 11;20(6):e0312893. doi: 10.1371/journal.pone.0312893. eCollection 2025.
4
COVID-19 vaccines for high risk and immunocompromised patients.
Methods Microbiol. 2022;50:269-279. doi: 10.1016/bs.mim.2021.11.001. Epub 2022 Jan 28.
5
Public Discourse, User Reactions, and Conspiracy Theories on the X Platform About HIV Vaccines: Data Mining and Content Analysis.
J Med Internet Res. 2024 Apr 3;26:e53375. doi: 10.2196/53375.
6
COVID-19 vaccines: history of the pandemic's great scientific success and flawed policy implementation.
Monash Bioeth Rev. 2024 Jun;42(1):28-54. doi: 10.1007/s40592-024-00189-z. Epub 2024 Mar 9.
7
Vaccine Strategies to Elicit Mucosal Immunity.
Vaccines (Basel). 2024 Feb 13;12(2):191. doi: 10.3390/vaccines12020191.
8
Comparative Analysis of Primary and Monovalent Booster SARS-CoV-2 Vaccination Coverage in Adults with and without HIV in Catalonia, Spain.
Vaccines (Basel). 2023 Dec 30;12(1):44. doi: 10.3390/vaccines12010044.
9
COVID-19 immunity and vaccines: what a pharmacist needs to know.
Asian Biomed (Res Rev News). 2021 Apr 30;15(2):51-67. doi: 10.2478/abm-2021-0008. eCollection 2021 Apr.
10
Advances in Research on COVID-19 Vaccination for People Living with HIV.
Infect Dis Immun. 2022 Oct;2(4):213-218. doi: 10.1097/ID9.0000000000000065. Epub 2022 Sep 1.
本文引用的文献
1
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Lancet. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020 May 22.
2
Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection.
PLoS Pathog. 2018 Feb 23;14(2):e1006888. doi: 10.1371/journal.ppat.1006888. eCollection 2018 Feb.
3
Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.
PLoS One. 2015 Sep 14;10(9):e0137666. doi: 10.1371/journal.pone.0137666. eCollection 2015.
4
The inner foreskin of healthy males at risk of HIV infection harbors epithelial CD4+ CCR5+ cells and has features of an inflamed epidermal barrier.
PLoS One. 2014 Sep 30;9(9):e108954. doi: 10.1371/journal.pone.0108954. eCollection 2014.
5
Immunology. Immune activation with HIV vaccines.
Science. 2014 Apr 4;344(6179):49-51. doi: 10.1126/science.1250672.
6
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.
N Engl J Med. 2013 Nov 28;369(22):2083-92. doi: 10.1056/NEJMoa1310566. Epub 2013 Oct 7.
7
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study).
J Infect Dis. 2012 Jul 15;206(2):258-66. doi: 10.1093/infdis/jis342. Epub 2012 May 4.
8
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.
J Clin Invest. 2012 Jan;122(1):359-67. doi: 10.1172/JCI60202. Epub 2011 Dec 27.
9
Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.
J Virol. 2012 Feb;86(4):2239-50. doi: 10.1128/JVI.06175-11. Epub 2011 Dec 7.
10
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.
Lancet Infect Dis. 2011 Jul;11(7):507-15. doi: 10.1016/S1473-3099(11)70098-6. Epub 2011 May 11.
Zotero 插件